News NICE rejects Bayer and Eisai drugs in thyroid cancer Thyroid cancer drugs are available in Scotland and Wales
News NICE wants to axe funding for two thyroid cancer drugs NICE unconvinced by survival data from Ipsen and Sanofi drugs
News Takeda preps for further acquisition Japanese firm has set money aside for emerging markets M&A.
News Eisai angry over thyroid cancer drug impasse in England Thyroid cancer drug falls through gap in NHS funding
News Ottimo raises $140m for its PD-1/VEGF cancer drug Ottimo raises $140m for PD-1 and VEGF-targeting jankistomig, which the startup says is differentiated from bispecific antibodies in the class.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
